[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525103":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":24,"armGroups":20,"interventions":25,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":56,"collaborators":59,"id":61,"slug":20,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":20,"maxAge":20,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":20,"briefSummary":73,"conditions":74,"keywords":20,"overallStatus":43,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of Helsinki","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":20},[9,13],{"measure":10,"description":11,"timeFrame":12},"Recruitment and collection of real-world clinical data from ovarian cancer patients","Prospective recruitment and collection of clinical data from 500 ovarian cancer patients. Fraction of patients from which the collection of clinical data including patient age, tumor stage, histological diagnoses have been collected.","5 years",{"measure":14,"description":15,"timeFrame":12},"Successful collection and translational analysis of biospecimens","Fraction of the recruited patients, from which tumor, ascites, and\u002For peripheral blood samples that have been successfully collected and subjected to molecular profiling.",[17],{"measure":18,"description":19,"timeFrame":12},"Discovery of candidate prognostic and predictive biomarkers","Number of clinical and\u002For molecular features which of statistically significantly correlate to patient treatment outcomes (response to chemotherapy by RECIST1.1, Progression Free survival, Overall Survival).",null,{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":22,"timePerspective":23,"maskingInfo":20},"COHORT","PROSPECTIVE","All ovarian cancer patients who give their informed consent to the study.",[26],{"type":27,"name":28,"description":29,"armGroupLabels":20,"otherNames":20},"GENETIC","Biomolecular profiling","Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.",[31],{"name":32,"affiliation":33,"role":34},"Anniina Färkkilä, MD PhD","Helsinki University Central Hospital","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":20,"email":39},"CONTACT","+358504272060","anniina.farkkila@helsinki.fi",[41],{"facility":42,"status":43,"city":44,"state":20,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Helsinki University and Helsinki University Hospital","RECRUITING","Helsinki","00014","Finland","FI",{"type":49,"coordinates":50},"Point",[51,52],24.93545,60.16952,{"lat":52,"lon":51},[55],{"name":32,"role":37,"phone":38,"phoneExt":20,"email":39},{"type":34,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Anniina Färkkilä","Assistant Professor, Specialist in Gynecology",[60],{"name":33,"class":6},"100525103",false,"NCT06117384","Systems Oncology Approach to Optimize Ovarian Cancer Treatment","ONCOSYS-OVA","Inclusion Criteria:\n\n* Patients diagnosed with ovarian cancer\n* Available tumor tissue\u002Fblood samples\n\nExclusion Criteria:\n\n* Inability to consent to the study","FEMALE",{"count":69,"type":70},500,"ESTIMATED","5 Years","OBSERVATIONAL","The overall aim is to identify effective therapeutic strategies to ovarian cancer (OC) using serial tumor, ascites and blood samples, and carry out state-of-the-art sequencing approaches, functional assays and associated bioinformatics to understand mechanisms behind chemoresistance in OC and identify new treatment options for OC patients. In this observational trial, we will systematically collect, analyze and interpret functional, molecular and clinical data from real-world ovarian cancer patients.",[75],"Ovarian Cancer","2023-11-01",{"date":78,"type":79},"2023-11-07","ACTUAL",{"date":81,"type":79},"2022-01-01",{"date":83,"type":70},"2027-12-31",{"name":5,"class":6},1]